Transient increase in plasma HIV-1 viral load and associated weight gain after thalidomide dosing [1]

AIDS

Volumn 16, Issue 17, 2002, Pages 2355-2356

  Teo, Steve ^a   Noormohamed, Faruq ^b   Youle, Mike ^c   Johnson, Margaret ^c   Peters, Barry ^d   Stirling, David ^a   Thomas, Steve ^a  

^a CELGENE CORPORATION   (United States)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; THALIDOMIDE;

ADULT; CLINICAL ARTICLE; CONTRACEPTION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LETTER; LYMPHOCYTE COUNT; MALE; NONHUMAN; OUTCOMES RESEARCH; PATIENT COUNSELING; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VIRUS LOAD; WEIGHT GAIN;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; THALIDOMIDE; VIRAL LOAD; WEIGHT GAIN;

EID: 0037159878     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200211220-00024     Document Type: Letter

References (11)

1. Gunzler V. Thalidomide in human immunodeficiency virus patients: A review of safety considerations. Drug Safety 1992, 7:116-134.
2. Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. N Engl J Med 1997, 336:1487-1493.
3. Haslett P, Hempstead M, Seideman C, et al. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with human immunodeficiency virus. AIDS Res Hum Retroviruses 1997, 13:1047-1054.
4. Reyes-Teran G, Sierra-Madaro JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trial. AIDS 1996, 10:1501-1507.
5. Teo SK, Chandula RS, Harden JL, et al. Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Chrom B 2002, 767:145-151.
6. Kaplan G, Thomas S, Fierer DS, et al. Thalidomide for the treatment of AIDS-associated wasting. AIDS Res Hum Retroviruses 2000, 14:1345-1355.
7. Noormohamed FH, Youle MS, Higgs CJ, et al. Pharmacokinetics and hemodynamlc effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected patients. AIDS Res Hum Retroviruses 1999, 15:1047-1052.
8. Kobayashi S, Hamamoto Y, Kobayashi N, Yamamoto N. Serum levels of TNF-α in HIV-infected individuals. AIDS 1990, 4: 169-170.
9. Kaplan G, Moreira A. TNF-α regulation of HIV-1: Biology and therapy. Res Immunol 1994, 145:685-690.
10. Tufariello JM, Cho S, Horwitz MS. Adenovirus E3 14.7-kilodalton protein, an antagonist of tumor necrosis factor cytolysis, increases the virulence of vaccinia virus in severe combined immunodeficient mice. Proc Natl Acad Sci USA 1994, 91:10987-10991.
11. Gooding LR, Elmore LW, Tollefson AE, Brady HA, Wold WSM. A 14,700 MW protein from the E3 region of adenovirus inhibits cytolysis by tumour necrosis factor. Cell 1988, 53:341-346.